Next Article in Journal
Controversies and Advances in Gestational Diabetes—An Update in the Era of Continuous Glucose Monitoring
Previous Article in Journal
The Evolving Treatment of Peripheral Arterial Disease through Guideline-Directed Recommendations
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessFeature PaperCase Report
J. Clin. Med. 2018, 7(1), 10; https://doi.org/10.3390/jcm7010010

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab

1
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2
David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
3
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
4
The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
*
Author to whom correspondence should be addressed.
Received: 19 December 2017 / Revised: 30 December 2017 / Accepted: 3 January 2018 / Published: 10 January 2018
View Full-Text   |   Download PDF [2291 KB, uploaded 16 January 2018]   |  

Abstract

Cutaneous squamous cell carcinomas (SCC) affecting the regions of the head and neck can be challenging to resect surgically and refractory to chemotherapy or radiation therapy. Consequently; the treatment of squamous cell carcinomas of the skin is a focus of current research. One such advancement is immunotherapy. Herein we describe clinical remission of invasive, poorly differentiated squamous cell carcinoma of the pre-auricular region with external auditory canal involvement using cetuximab, an epidermal growth factor receptor (EGFR) antibody; and nivolumab, a programmed death receptor-1 (PD-1) antibody. Such durable and comprehensive disease resolution demonstrates the therapeutic potential of cetuximab and nivolumab in surgically challenging, treatment-resistant cutaneous squamous cell carcinoma. View Full-Text
Keywords: cutaneous squamous cell carcinoma; cetuximab; nivolumab cutaneous squamous cell carcinoma; cetuximab; nivolumab
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chen, A.; Ali, N.; Boasberg, P.; Ho, A.S. Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. J. Clin. Med. 2018, 7, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top